Breaking News
Get 50% Off 0
📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-Earnings Read more
Close

Mankind Pharma Ltd (MNKI)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2,138.90 +24.40    +1.15%
- Closed. Currency in INR ( Disclaimer )
Type:  Equity
Market:  India
ISIN:  INE634S01028 
S/N:  MANKIND
  • Volume: 5,390
  • Bid/Ask: 2,138.90 / 2,140.00
  • Day's Range: 2,116.30 - 2,141.75
Mankind Pharma 2,138.90 +24.40 +1.15%

BO:MNKI Financials

 
A brief overview of the BO:MNKI financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Mankind Pharma Ltd over time.

Mankind Pharma Limited reported earnings results for the fourth quarter and full year ended March 31, 2024. For the fourth quarter, the company reported sales was INR 24,410.99 million compared to INR 20,526.67 million a year ago. Revenue was INR 25,332.27 million compared to INR 21,001.78 million a year ago. Net income was INR 4,712.39 million compared to INR 2,854.39 million a year ago. Basic earnings per share from continuing operations was INR 11.76 compared to INR 7.13 a year ago. Diluted earnings per share from continuing operations was INR 11.74 compared to INR 7.13 a year ago.For the full year, sales was INR 103,347.75 million compared to INR 87,494.33 million a year ago. Revenue was INR 106,156.33 million compared to INR 88,780 million a year ago. Net income was INR 19,128.97 million compared to INR 12,818.59 million a year ago. Basic earnings per share from continuing operations was INR 47.75 compared to INR 32 a year ago. Diluted earnings per share from continuing operations was INR 47.68 compared to INR 32 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

MNKI Income Statement

Gross margin TTM 68.94%
Operating margin TTM 20.68%
Net Profit margin TTM 18.51%
Return on Investment TTM 18.72%
 Total Revenue  Net Income
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Revenue 24410.99 26069.59 27080.99 25786.18
Gross Profit 17038.11 17793.7 18832.39 17586.6
Operating Income 4864.16 4967.8 5861.62 5674.61
Net Income 4712.38 4537.6 5010.26 4868.72

MNKI Balance Sheet

Quick Ratio MRQ 2.03
Current Ratio MRQ 3.1
LT Debt to Equity MRQ 0.27%
Total Debt to Equity MRQ 2.21%
 Total Assets  Total Liabilities
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Assets 119632.55 110983.24
Total Liabilities 23874.67 24647.34
Total Equity 95757.88 86335.9 86335.9 76232.93

MNKI Cash Flow Statement

Cash Flow/Share TTM 53.73
Revenue/Share TTM 257.99
Operating Cash Flow  0.00%
 Cash  Net Change in Cash
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change in Cash
* In Millions of INR (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MNKI Comments

Write your thoughts about Mankind Pharma Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Rawan Kumar
Rawan Kumar May 14, 2023 12:16PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
tomorrow us confirm
Sanjay Gupta
Sanjay Gupta May 09, 2023 11:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
feeling sorry now for exiting too early.. 😭😭
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email